RTW Investments LP Buys Shares of 148,844 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

RTW Investments LP bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the third quarter, HoldingsChannel reports. The institutional investor bought 148,844 shares of the company’s stock, valued at approximately $2,300,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $42,000. MetLife Investment Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $135,000. Charles Schwab Investment Management Inc. purchased a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $623,000. Finally, Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $680,000.

Artiva Biotherapeutics Price Performance

Shares of ARTV stock opened at $12.72 on Thursday. The stock’s fifty day moving average price is $12.56. Artiva Biotherapeutics, Inc. has a 12 month low of $9.68 and a 12 month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ARTV. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Jefferies Financial Group initiated coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price target for the company. TD Cowen initiated coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating for the company. Cantor Fitzgerald initiated coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.